Related Experiment Video

Updated: Jan 12, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

Emerging Therapeutic Targets for Platinum-Resistant Ovarian Cancer

Connor C Wang1, Maria Gomez-Roas1, Emily M Hinchcliff1

  • 1Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, 250 East Superior Street, Suite 05-2185, Chicago, IL 60611, USA.

Hematology/Oncology Clinics of North America
|October 31, 2025
PubMed

Insights

Recurrent platinum-resistant ovarian cancer poses a major challenge. This review explores resistance mechanisms and novel therapies, including combination strategies and biomarkers, to improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Recurrent platinum-resistant ovarian cancer has poor treatment responses and survival.
  • Platinum resistance involves complex biological mechanisms.
  • Limited effective therapeutic options exist for this patient group.

Purpose of the Study:

  • To comprehensively review the biological mechanisms of platinum resistance in ovarian cancer.
  • To discuss emerging therapies and combination strategies targeting these mechanisms.
  • To highlight advances in overcoming platinum resistance through biomarker-driven approaches.

Main Methods:

  • Literature review of biological mechanisms of platinum resistance.
  • Analysis of emerging therapies and combination strategies.
  • Review of clinical trial data and biomarker research.

Main Results:

  • Detailed exploration of resistance mechanisms: DNA repair, drug transport, apoptosis evasion, tumor microenvironment, and cancer stem cells.
  • Discussion of novel therapies targeting these mechanisms.
  • Emphasis on combination therapies and personalized treatment strategies.

Conclusions:

  • Understanding platinum resistance mechanisms is crucial for developing new treatments.
  • Emerging therapies and combination strategies show promise.
  • Biomarker-driven and personalized approaches are key to improving outcomes in recurrent platinum-resistant ovarian cancer.
Keywords:
Chemotherapy resistancePlatinum-resistant ovarian cancerRecurrent ovarian cancerTargeted therapy

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.7K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K